Reconciling global-model estimates and country reporting of anthropogenic forest CO2 sinks

This is the author accepted manuscript. The final version is available from Springer Nature via the DOI in this recordData availability: The data that support the findings of this study are available from the corresponding author upon request.Achieving the long-term temperature goal of the Paris Agreement requires forest-based mitigation. Collective progress towards this goal will be assessed by the Paris Agreement’s Global stocktake. At present, there is a discrepancy of about 4 GtCO2yr−1in global anthropogenic net land-use emissions between global models (reflected in IPCC assessment reports) and aggregated national GHG inventories (under the UNFCCC). We show that a substantial part of this discrepancy (about 3.2 GtCO2yr−1) can be explained by conceptual differences in anthropogenic forest sink estimation, related to the representation of environmental change impacts and the areas considered as managed. For a more credible tracking of collective progress under the Global stocktake, these conceptual differences between models and inventories need to be reconciled. We implement a new method of disaggregation of global land model results that allows greater comparability with GHG inventories. This provides a deeper understanding of model–inventory differences, allowing more transparent analysis of forest-based mitigation and facilitating a more accurate Global stocktake.J.H. was supported by EU FP7 through project LUC4C (GA603542) and the UK NERC project GGRiLS-GAP. G.G. was supported by Administrative Arrangement Number 340203/2016/742550/SER/CLIMA.A3. A.K.J. was supported by the NSF (AGS 12-43071) and DOE (DE-SC0016323). J.E.M.S.N. was supported by the German Research Foundation’s Emmy Noether Programme (grant number PO1751/1-1). G.G., J.H., G.P.P. and L.P. received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 776810 (VERIFY). C.D.K. was supported by the US DOE under Contract DE-AC02-05CH11231 as part of their RGMA (BGC-Feedbacks SFA) and TES Programs (NGEE-Tropics). A.K.J. was supported under the US NSF (NSF-AGS-12-43071)

Is Area-Wide Pest Management Useful? The Case of Citrus Greening.

Citrus greening currently poses a severe threat to citrus production worldwide. No treatment or management strategy is yet available to cure the disease. Scientists recommend controlling the vector of the disease, and area-wide pest management has been proposed as a superior alternative to individual pest management. We analyzed a unique dataset of farm-level citrus yields that allowed us to test this hypothesis. We found that yields of blocks located in an area with higher participation in coordinated sprays were 28%, 73% and 98% percent higher in 2012/13, 2013/14, and 2014/15, respectively, compared to the yields of blocks under the same management but located in an area with lower participation; providing evidence on the efficiency of a well-performing pest management area to deal with HLB. However, participation in CHMAs has not been commensurate with this evidence. We present survey data that provide insights about producers’ preferences and attitudes toward the area-wide pest management program. Despite the economic benefit we found area-wide pest management can provide, the strategic uncertainty involved in relying on neighbors seems to impose too high of a cost for most growers, who end up not coordinating sprays

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

BACKGROUND: Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced. METHODS: In this follow up study, plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data. FINDINGS: Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months (p < 0.0001). Nasal and plasma anti-S IgG remained elevated for at least 12 months (p < 0.0001) with plasma neutralising titres that were raised against all variants compared to controls (p < 0.0001). Of 323 with complete data, 307 were vaccinated between 6 and 12 months; coinciding with rises in nasal and plasma IgA and IgG anti-S titres for all SARS-CoV-2 variants, although the change in nasal IgA was minimal (1.46-fold change after 10 months, p = 0.011) and the median remained below the positive threshold determined by pre-pandemic controls. Samples 12 months after admission showed no association between nasal IgA and plasma IgG anti-S responses (R = 0.05, p = 0.18), indicating that nasal IgA responses are distinct from those in plasma and minimally boosted by vaccination. INTERPRETATION: The decline in nasal IgA responses 9 months after infection and minimal impact of subsequent vaccination may explain the lack of long-lasting nasal defence against reinfection and the limited effects of vaccination on transmission. These findings highlight the need to develop vaccines that enhance nasal immunity. FUNDING: This study has been supported by ISARIC4C and PHOSP-COVID consortia. ISARIC4C is supported by grants from the National Institute for Health and Care Research and the Medical Research Council. Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research. The PHOSP-COVD study is jointly funded by UK Research and Innovation and National Institute of Health and Care Research. The funders were not involved in the study design, interpretation of data or the writing of this manuscript

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

One in ten severe acute respiratory syndrome coronavirus 2 infections result in prolonged symptoms termed long coronavirus disease (COVID), yet disease phenotypes and mechanisms are poorly understood1. Here we profiled 368 plasma proteins in 657 participants ≥3 months following hospitalization. Of these, 426 had at least one long COVID symptom and 233 had fully recovered. Elevated markers of myeloid inflammation and complement activation were associated with long COVID. IL-1R2, MATN2 and COLEC12 were associated with cardiorespiratory symptoms, fatigue and anxiety/depression; MATN2, CSF3 and C1QA were elevated in gastrointestinal symptoms and C1QA was elevated in cognitive impairment. Additional markers of alterations in nerve tissue repair (SPON-1 and NFASC) were elevated in those with cognitive impairment and SCG3, suggestive of brain–gut axis disturbance, was elevated in gastrointestinal symptoms. Severe acute respiratory syndrome coronavirus 2-specific immunoglobulin G (IgG) was persistently elevated in some individuals with long COVID, but virus was not detected in sputum. Analysis of inflammatory markers in nasal fluids showed no association with symptoms. Our study aimed to understand inflammatory processes that underlie long COVID and was not designed for biomarker discovery. Our findings suggest that specific inflammatory pathways related to tissue damage are implicated in subtypes of long COVID, which might be targeted in future therapeutic trials

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Behavior and Design of Deep Structural Members Part 6: The Yield Strength of Intermediate Grade Reinforcing Bars Under Rapid Loading

Research Directorate, Air Force Special Weapons Center. Kirtland Air Force Base.Contract AF 29(601)-468Project 108

Investigation of Resistance and Behavior of Reinforced Concrete Members Subjected to Dynamic Loading: Part III

Defense Atomic Support AgencyOffice of the Chief of Engineers, U.S. Army.Contract DA 49-129-Eng-34